Cardiometabolic Disease and COVID-19: Risk, Treatment and Trials

Cardiometabolic Disease and COVID-19: Risk, Treatment and Trials

The effect of COVID and metabolic disease and early treatment

Dr Mikhail N Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) joins Prof Hertzel Gerstein (McMaster University, Hamilton, ON, CA) to discuss the current landscape of cardiometabolic therapies for COVID-19. Dr Kosiborod talks about the cardiometabolic risk factors for death in people who are hospitalised with COVID-19.
Recorded remotely from Hamilton and Kansas City, 2020.
This discussion was supported by an unrestricted educational grant from Novo Nordisk.

 


Programme Outline
  • The effect of COVID and metabolic disease and early treatmentMikhail KosiborodHertzel C Gerstein
  • Metabolic therapy treatmentsMikhail KosiborodHertzel C Gerstein
  • Phase III DARE-19 trialMikhail KosiborodHertzel C Gerstein
This discussion was supported by an unrestricted educational grant from Novo Nordisk.

Metabolic therapy treatments

Play Next